

North Central Cancer Treatment Group

N0776: Phase II Trial of Avastin® in Combination with Sorafenib in Recurrent Glioblastoma Multiforme

Update 2 – December 4, 2009

Summary

- With NCCTG Addendum 10, an additional blood draw for CECs was added at the timepoint if the patient's disease worsens. This change was not carried over to the NCCTG Consent Form. This has now been corrected.
- Administrative/editorial changes.

Replacement pages are included. Please incorporate into the protocol and keep this addendum with your protocol

Title page Updated to reflect the addition of Update 2 revised NCI version date.

Appendix I **Consent Form**
Page 4: With Addendum 10, an additional blood draw for CECs was added, but was not carried over to the NCCTG Consent Form. This has been corrected in the "During the study" as follows:
Blood samples will be collected before treatment begins;; Cycle 1 Day 3;; before treatment Cycle 2;; before treatment Cycle 3;; ~~and then~~ before treatment every 4 weeks times 5 (before treatment Cycles 5, 7, 9, 11, and 13); **and when your disease may worsen, you withdraw from the study, or are removed from the study.**